Soleno Therapeutics, Inc.

Total Valuation

Soleno Therapeutics, Inc. carries a market capitalization of 2.76B, placing it among publicly traded companies globally. Its enterprise value stands at 1.55B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Soleno Therapeutics, Inc. currently has 51.72M shares outstanding.

Valuation Ratios

Soleno Therapeutics, Inc. trades at a trailing price-to-earnings ratio of 18.22. The price-to-sales ratio is 6.14, and the price-to-book ratio stands at -4.38.

Enterprise Valuation

On an enterprise value basis, Soleno Therapeutics, Inc. trades at an EV/EBITDA multiple of 16.92 and an EV/FCF ratio of 13.97. The EV/Sales ratio of 5.43 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 17.31 provides insight into valuation relative to core operating earnings.

Financial Position

Soleno Therapeutics, Inc. maintains a current ratio of 5.62, meaning it holds 5.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 10.95, indicating elevated leverage, while an interest coverage ratio of 16.93 demonstrates strong ability to service its debt obligations.

Financial Efficiency

Taxes

Over the trailing twelve months, Soleno Therapeutics, Inc. has paid 3.54M in income taxes, reflecting an effective tax rate of 3.55.

Stock Price Statistics

Soleno Therapeutics, Inc.'s stock has declined approximately -31.50278% over the past 52 weeks. The 50-day moving average sits at 45.78, while the 200-day moving average is 51.16.

Income Statement

Over the trailing twelve months, Soleno Therapeutics, Inc. generated 285.01M in revenue and converted that into 96.04M in net income, yielding earnings per share of 1.81. EBITDA reached 91.52M, while operating income came in at 89.49M.

Balance Sheet

Soleno Therapeutics, Inc. holds 255.60M in cash and equivalents against 54.28M in total debt, resulting in a net debt position of -83.15M. Total book value stands at -399.94M, with working capital of 268.33M providing operational flexibility.

Cash Flow

Soleno Therapeutics, Inc. produced 105.53M in operating cash flow over the past twelve months. After subtracting -108,000.00 in capital expenditures, free cash flow totaled 105.42M - equivalent to 2.02 per share.

Margins

Soleno Therapeutics, Inc. operates with a gross margin of 98.63, reflecting its pricing power and cost economics. The operating margin of 31.40 and net profit margin of 33.70 provide insight into operational efficiency.

Dividends & Yields

Stock Splits

Soleno Therapeutics, Inc.'s most recent stock split took place on August 26, 2022 with a 15:1 split ratio.

Scores

Soleno Therapeutics, Inc. posts an Altman Z-Score of 9.89, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.